Unlikely bedfellows join to fight superbugs
In January 2016, more than 100 companies and industry associations had signed a Declaration on Combatting Antimicrobial Resistance at the World Economic Forum in Davos, followed by a Roadmap of several big pharma at the UN High-Level Meeting in September 2016 – a common framework of principles for global measures to curb the development of antibiotic resistance. The “AMR Industry Alliance” now...
Read more68th WHO Regional Committee for Europe: Roadmap for access 2019–2023: Comprehensive support for access to medicines and vaccines
September 20, 68th WHO Regional Committee for Europe Delivered by Sara Amini, Senior Manager, Social and Economic Policy, IFPMA IFPMA represents R&D-based biopharmaceutical industry worldwide and will provide the position and perspective of the global biopharmaceutical industry. IFPMA welcomes the WHO’s ambitious 13th General Programme of Work (GPW), particularly around delivery of UHC. A broad...
Read more25th IFPMA assembly explores theme of “A shared commitment to global health”
The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) held its 25 th Assembly today in Washington DC, USA. This biannual event brought together CEOs and senior figures from IFPMA member companies and associations. They were joined by senior figures from intergovernmental organizations, national governments, the Washington diplomatic community and health-related NGOs. IFPMA Director General,...
Read moreWhy we must invest in UHC
For millions of people worldwide out-of-pocket health expenses translate to out-of-reach opportunities for the future. Children miss out on essential immunizations, women die giving birth in unsafe environments, and people are at risk of going blind or having a stroke before they realize they are not properly controlling their diabetes. To quote Dr Tedros Adhanom...
Read moreFour innovators awarded Africa Young Innovators for Health Award for contributions to Universal Health Coverage
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and Speak Up Africa have announced the winners of the second edition of the Africa Young Innovators for Health Award.
Read more
WHO Afro 68 agenda item 14: Roadmap for access 2019–2023: Comprehensive support for access to medicines and vaccines
Delivered by Cyntia Genolet, Senior Manager Global Health Policy, IFPMA Thank you for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations across the world, including three in Africa. The IFPMA welcomes the WHO’s ambitious 13 General Programme of Work, which...
Read moreRegulatory agilities applied to quality processes
This policy briefing summarizes trends in reported experiences (from primary and secondary research) in the use of regulatory agilities applied to quality observed since the start of the pandemic, some reported challenges to their implementation and forward-looking recommendations, whether to prepare for the next pandemic or strengthen standard normative processes to accelerate patient access to safe and effective medicines and vaccines.
Read more
Pulling Together To Thwart A Silent Killer
This blog was first published on Life Science Leader on 22 January 2018 As we start 2018, those of us in the healthcare sector are anticipating greater progress in global health. Without a doubt, healthcare has been transformed over the past five decades, through innovation in both prevention and treatment of disease, as well as...
Read moreIFPMA statement on climate change and health
The driving motivation of the pharmaceutical industry is to improve human health and well-being. Climate change will challenge the global community in its efforts to tackle health concerns and inequalities across the world. It can have consequences both for people living today, especially the poorest and most vulnerable, and for future generations. It is...
Read moreResearch-based pharmaceutical industry emergency aid for Japan earthquake and tsunami victims
The global research-based pharmaceutical industry represented by the IFPMA is providing significant funds to relief organisations following the major earthquake that struck Japan on 11 March 2011. The total cash value of assistance provided so far by IFPMA member companies already amounts to over USD 40 million, and several companies have also donated medicines and...
Read more